VLS - selection of Comments to Shareholders/ market
21 Aug 2017 -
Profit for half year down 17.5%
Period of transformational change for the organisation in the first half performance
Key leaderships positions filled across the business including, CEO Asia, CFO, VLS Head of Marketing
Management remains confident in its strategy and takes a longer term view around future growth prospects
Directors provide the following guidance for the 2017 full year;
Full year revenue guidance of ∼$38m;
Full year EBIT guidance of $5.0m to $5.5m.
9 Aug 2017
Appointment of Asian CEO
18May 2017 – AGM
task of the Board of Directors is to steer the Company’s strategy of long term growth in sales revenue and profitability,
Our Australian Herbs of Gold brand is now well placed to penetrate the China market as a result of entering into an exclusive arrangement with Jointown Pharmaceutical Group Co Ltd for distribution in China.
Appointment of Asia CEO - This will be a crucial role in driving the performance for both the established and emerging markets within the region.
13 Oct 2016
Andrew O’Keefe – Acting MD then MD from 1 Jan 2017.
22 Aug 2016
China: Whilst regulatory issues continued the Group is exploring business options to enter this markets
12 May 2016
Build a sustainable business in each country where operations have been established, however remain in their infancy
Malaysia & Singapore - Identify opportunities to leverage Group’s position into new customer groups
VLS Price at posting:
74.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)